Mutations in the EGFR gene and overexpression of ErbB2 have been observed in CRC, leading to the activation of downstream signaling pathways that promote cell proliferation, drug resistance and metastasis [71]. The gene discussed is ERBB2; the disease is colorectal carcinoma.